Alder Biopharmaceuticals, Inc.
USPTO PatentsView assignee record - 5 granted patents across 7 technology areas, recorded in grant years 2017–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).
The verdict
According to USPTO PatentsView, Alder ranks #44,567 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 7 technology areas.
- #44,567
- of 49,997 US assignees by volume
- 11th percentile
- by Innovation Score (23.0/100)
- 12.4
- avg claims per patent
- -75%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R44567 · US Corporation #44,567 · 5 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 5 grants
- LOWER-Q #44,567/49,997
- PHOTO-FINISH Akwel Sweden AB
- CPC-NARROW C07K · 7 areas
- INNOV-THIN 23.0/100
- CLAIMS-RICH 12.4 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -75% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Akwel Sweden AB (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Alder’s 23.0 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Alder
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Alder Biopharmaceuti… · this assignee 23
Alder Biopharmaceuti… · this assignee
23 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Alder's Innovation Score is 23.0/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Alder?
Each dot is one of Alder’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Alder’s own 12.4 claims/patent is at or below the 14.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Alder's grants concentrate
Alder Biopharmaceuticals, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 80% of grants classified under C07K (Peptides). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2017. By volume, Alder sits between Akwel Sweden AB and Alerje, Inc..
Who files at Alder's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Akwel Sweden AB
Akwel Sweden AB
5 patents
- Albea Lacrost
Albea Lacrost
5 patents
- Albert Einstein H…
Albert Einstein Healthcare Network
5 patents
- Alcon Components
Alcon Components Limited
5 patents
- Aleees ECO ARK
Aleees ECO ARK Co. Ltd.
5 patents
- Alef Edge
Alef Edge Inc
5 patents
- Alere
Alere Technologies GMBH
5 patents
- Alerje
Alerje, Inc.
5 patents
- Alder Biopharmace… ◀
Alder Biopharmaceuticals, Inc.
5 patents
What this shows Alder holds 5 patents at rank #44,479, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Alder
By rank, the assignees closest to #44,479 in granted patent volume.
- Akwel Sweden AB #44,475 · 5 patents
- Albea Lacrost #44,476 · 5 patents
- Albert Einstein Healthcare Network #44,477 · 5 patents
- Alcon Components Limited #44,478 · 5 patents
- Aleees ECO ARK Co. Ltd. #44,480 · 5 patents
- Alef Edge Inc #44,481 · 5 patents
- Alere Technologies GMBH #44,482 · 5 patents
- Alerje, Inc. #44,483 · 5 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Alder's primary technology class.
- The Regents of the University of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies GmbH 678 in class
- Genentech, Inc. 565 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 513 in class
- The Trustees of the University of Pennsylvania 501 in class
- Novartis AG 407 in class
- The Board of Trustees of the Leland Stanford Junior University 400 in class
Alder's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
23 11th percentile higher than 11% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 20.0% |
| 2018 | 1 | 20.0% |
| 2019 | 2 | 40.0% |
| 2020 | 1 | 20.0% |
Which technologies does Alder Biopharmaceuticals, Inc. patent most?
Top 7 of 7 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Alder Biopharmaceuticals, Inc.'s patent record in context - here's where to go next.
- Alder Biopharmaceuticals, Inc.'s lead technology class is C07K (Peptides), 80% of its portfolio - see every assignee active in that class. Explore C07K
- Ranked #44,567 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Alder Biopharmaceuticals, Inc. against Akwel Sweden AB, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 23.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.